Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database.
Résumé
As shown by Kostine et al,1 and recently underlined by Ceccarelli et al,2 rheumatic inflammatory disorders induced by anticancer therapy are becoming a major concern for rheumatologists at the era of immune checkpoint inhibitors (ICIs). Beyond inflammatory arthritis, which may concern 10%–20% of patients, myositis represents a rare (<1%) but potentially life-threatening event. We thus aimed at investigating the risk of ICI-related myositis in real-life setting using VigiBase, the WHO’s pharmacovigilance database.
Fichier principal
10.1136annrheumdis-2020-217018 Myositis ICI - 20200116 ARD correspondence - JLF.pdf (115.47 Ko)
Télécharger le fichier
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|